MINI FUTURE LONG - NOVO-NORDISK B | Real-time Euronext Paris 05:38:19 2024-06-03 EDT | ||
| 13.72 EUR | -2.11% |
|
| 1 month | +6.26% | ||
| 3 months | +23.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 13.72 | -2.11% |
| 24-05-31 | 14.01 | +1.05% |
| 24-05-30 | 13.86 | +0.95% |
| 24-05-29 | 13.74 | -0.87% |
| 24-05-28 | 13.86 | -0.68% |
Real-time Euronext Paris
Last update June 03, 2024 at 05:38 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| I0NKB | |
| ISIN | FRBNPP05EC66 |
| Date issued | 2023-02-15 |
| Strike | 406.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.46 € |
|---|---|
| Lowest since issue | 2.885 € |
| Spread | 0.01 € |
| Spread % | 0.07% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- I0NKB Certificat
